Login to Your Account

No Signal for Others in Class

JAK ‘Sprat’ Out by Sanofi; Safety Issue Off-Target, Analyst Says

By Randy Osborne
Staff Writer

Monday, November 18, 2013
Less than a week after Cell Therapeutics Inc. (CTI) snagged a handsome deal with Baxter International Inc. for its Janus kinase (JAK) inhibitor pacritinib – adding another industry vote for the approach – Sanofi SA disclosed safety problems with its JAK inhibitor fedratinib and ended the Phase III effort, which sparked a new look at the class.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription